These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30257357)

  • 1. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
    Xu ZH; Yao TZ; Liu W
    Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
    Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
    Li H; Dai S; Zhen T; Shi H; Zhang F; Yang Y; Kang L; Liang Y; Han A
    Eur J Cancer; 2014 Apr; 50(6):1207-21. PubMed ID: 24412052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-378a-3p enhances adipogenesis by targeting mitogen-activated protein kinase 1.
    Huang N; Wang J; Xie W; Lyu Q; Wu J; He J; Qiu W; Xu N; Zhang Y
    Biochem Biophys Res Commun; 2015 Jan; 457(1):37-42. PubMed ID: 25529446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
    Chen J; Li G
    Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of miR-378a-3p induces decidual cell apoptosis: a possible mechanism for early pregnancy loss.
    Hong L; Yu T; Xu H; Hou N; Cheng Q; Lai L; Wang Q; Sheng J; Huang H
    Hum Reprod; 2018 Jan; 33(1):11-22. PubMed ID: 29165645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes.
    Chen W; Du J; Li X; Su J; Huang Y; Ding N; Zhang M; Jiang S
    Pharmacogenomics; 2017 Dec; 18(18):1671-1682. PubMed ID: 29173002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
    Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
    Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
    J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4.
    Chanjiao Y; Chunyan C; Xiaoxin Q; Youjian H
    Immun Inflamm Dis; 2021 Mar; 9(1):108-119. PubMed ID: 33159506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.